Home  /  Resource Library  /  R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients > 60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients > 60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

Results of a study comparing chemoimmunotherapy treatments for first line treatment of DLBCL.